Gufic Biosciences Limited (BOM:509079)

Market Cap	31.04B
Revenue (ttm)	8.74B
Net Income (ttm)	569.19M
Shares Out	100.28M
EPS (ttm)	5.68
PE Ratio	54.54
Forward PE	n/a
Dividend	0.10 (0.03%)
Ex-Dividend Date	Sep 22, 2025

Volume	740
Average Volume	1,226
Open	311.00
Previous Close	314.75
Day's Range	309.30 - 314.65
52-Week Range	285.00 - 469.75
Beta	-0.01
RSI	38.21
Earnings Date	Nov 14, 2025

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (P...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 1,484
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 509079

Financial Performance

In 2024, Gufic Biosciences's revenue was 8.20 billion, an increase of 1.63% compared to the previous year's 8.07 billion. Earnings were 696.50 million, a decrease of -19.14%.